Ark Biosciences Initiates VICTOR Study
Ark Biosciences announced that dosing with AK0529, its leading antiviral drug against respiratory syncytial virus (RSV), has commenced in infants hospitalized with RSV infection in the VICTOR study...
know more >
Ark Biosciences' Anti-RSV AK0529 Successfully Completes Phase I Study
Ark Biosciences announced the successful completion of phase 1 clinical study of its anti-respiratory syncytial virus (RSV) drug AK0529...
know more >
Ark Biosciences Completes Series A Financing and Reports Significant Progress for AK0529
Ark Biosciences announced successful completion of a Series A financing...
know more >
Ark Biosciences Licenses Novel Drug Candidate from Roche for Potential Treatment of RSV infection
Ark Biosciences announced a licensing agreement for Roche's Respiratory Syncytial Virus (RSV) drug candidate AK0529...
know more >